All News
Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology
Over the years of navigating the annual meeting, I found the sessions with the most impact to my practice were the Plenary Sessions. During these sessions, the latest research is presented, new ideas are floated, and old myths debunked. Here are the top ACR2023 Plenary abstracts I found impactful for my practice.
Read ArticleSGLT2 inhibitors: The new hype in SLE and LN management?
Inhibitors of SGLT2 have been shown to reduce MACE in patients with type 2 DM and established cardiovascular disease. In patients with chronic kidney disease at risk of progression, SGLT2 inhibitors have shown reduction in risk of eGFR decline and hospitalization. In SLE, clinical trials have yet to explore the possible role of SGLT2i in improving renal outcomes in lupus nephritis. A couple of abstracts presented during the meeting tackled the topic of SGLT2 inhibition in SLE.
Read ArticleTheDaoIndex KDAO2011 ( View Tweet)
TheDaoIndex KDAO2011 ( View Tweet)
Eric Dein ( View Tweet)
TheDaoIndex KDAO2011 ( View Tweet)
#ACRbest Abstracts – Day 2
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more.
Read ArticleEric Dein ( View Tweet)
Eric Dein ( View Tweet)
Eric Dein ( View Tweet)
Eric Dein ( View Tweet)